MGMT and glioblastoma: However, there was no significant difference in the status of MGMT promoter methylation status between the two groups (50% MGMT promoter methylation in the 34 patients from the group of GBM plus non-CNS tumors compared to 38.2% in the 68 patients from the group of GBM only, p = 0.257).